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Primary cilia are required for Smoothened to trans-
duce vertebrate Hedgehog signals, but how Smooth-
ened accumulates in cilia and is activated is incom-
pletely understood. Here, we identify cilia-associated
oxysterols that promote Smoothened accumulation
in cilia and activate the Hedgehog pathway. Our data
reveal that cilia-associated oxysterols bind to two
distinct Smoothened domains to modulate Smooth-
ened accumulation in cilia and tune the intensity of
Hedgehog pathway activation. We find that the
oxysterol synthase HSD11b2 participates in the pro-
duction of Smoothened-activating oxysterols and
promotes Hedgehog pathway activity. Inhibiting oxy-
sterol biosynthesis impedes oncogenic Hedgehog
pathway activation and attenuates the growth of
Hedgehog pathway-associated medulloblastoma,
suggesting that targeted inhibition of Smoothened-
activating oxysterol production may be therapeuti-
cally useful for patients with Hedgehog-associated
cancers.
INTRODUCTION
Hedgehog proteins control developmental patterning and tissue
homeostasis in evolutionarily diverse organisms (Briscoe and316 Molecular Cell 72, 316–327, October 18, 2018 Published by ElseThe´rond, 2013). Misactivation of the Hedgehog (HH) pathway
can lead to cancers, including medulloblastoma, the most
common pediatric brain tumor, and basal cell carcinoma, the
most common tumor in the United States. In vertebrates, HH
signaling requires the primary cilium, an antenna-like projection
on the surface of most cells. HH ligands relieve Patched1
(PTCH1) repression of Smoothened (SMO), allowing SMO
to accumulate in cilia and activate GLI transcription factors
(Briscoe and The´rond, 2013). How SMO accumulates in cilia
and is activated is incompletely understood.
Sterol lipids are required for vertebrate HH signaling, and both
synthetic oxysterols and cholesterol can bind SMO to activate
the downstream pathway (Byrne et al., 2016; Cooper et al.,
2003; Corcoran and Scott, 2006; Dwyer et al., 2007; Huang
et al., 2016, 2018; Luchetti et al., 2016; Myers et al., 2013,
2017; Nachtergaele et al., 2012, 2013; Nedelcu et al., 2013;
Xiao et al., 2017). Synthetic oxysterols bind to the SMO N-termi-
nal extracellular cysteine-rich domain (CRD), cause SMO to
accumulate in cilia, activate the HH pathway, and stimulate the
growth of cultured medulloblastoma cells (Corcoran and Scott,
2006; Dwyer et al., 2007; Myers et al., 2013; Nachtergaele
et al., 2013; 2012; Nedelcu et al., 2013). Similarly, cholesterol
binds to the SMO CRD and can induce HH signaling in neural
progenitors, leading to the hypothesis that cholesterol is the
endogenous ligand that activates SMO (Byrne et al., 2016;
Huang et al., 2016, 2018; Luchetti et al., 2016). Phosphatidylino-
sitol 4-phosphate is enriched in the ciliary membrane, revealing
that the primary cilium can have a lipid composition distinct
from that of other cellular membranes (Cha´vez et al., 2015;vier Inc.
Garcia-Gonzalo et al., 2015). Therefore, we hypothesized that
oxysterols that activate SMO may be present in primary cilia
andmay stimulate the HH pathway specifically in this subcellular
context.
To define the oxysterol composition of cilia, we performed
mass spectrometry of the membranes of isolated cilia. We iden-
tified endogenous cilia-associated oxysterols that bind SMO,
cause SMO to accumulate in cilia, and activate the HH pathway.
Moreover, we found that cilia-associated oxysterols activate the
HH pathway through two separate domains of SMO. Either
genetic or pharmacologic inhibition of HSD11b2, an oxysterol
synthase, attenuates HH signal transduction and the growth of
HH pathway-associated medulloblastoma. Thus, oxysterols
found in primary cilia bind two distinct domains of SMO, cause
SMO to accumulate in cilia, and activate the HH pathway to pro-
mote the growth of medulloblastoma.
RESULTS
Identification of Cilia-Associated Oxysterols
To identify ciliary oxysterols, we biochemically isolated cilia from
sea urchin (Strongylocentrotus purpuratus) embryos, which
require cilia to transduce HH signals (Figures 1A and 1B; Sigg
et al., 2017; Warner et al., 2014). High-performance liquid chro-
matography-tandem mass spectrometry (HPLC-MS/MS) with
normalization to protein content revealed that sea urchin embryo
cilia are enriched in 7-keto-cholesterol (7k-C), 7b,27-dihydroxy-
cholesterol (7b,27-DHC), 24-keto-cholesterol (24k-C), and
24,25-epoxycholesterol (24,25-EC) compared to either whole
and de-ciliated embryos (Figures 1C, S1A, and S1B).
Cilia-Associated Oxysterols Bind to SMO, Activate the
Hedgehog Pathway, and Cause SMO to Accumulate
in Cilia
7k-C does not activate the HH pathway (Dwyer et al., 2007). As
the other oxysterols that were enriched in sea urchin embryo cilia
had not been previously investigated for roles in HH signaling,
we examined whether they were able to bind to SMO. We incu-
bated detergent-solubilized membranes from HEK293S cells
expressing SMOwith 20(S)-yne affinity resin and oxysterol com-
petitors. Both 7b,27-DHC and 24(S),25-EC competedwith 20(S)-
OHC for occupancy of the CRD, demonstrating that 7b,27-DHC
and 24(S),25-EC bind to SMO (Figure 1D).
TreatingciliatedNIH/3T3cellswith7b,27-DHCand24(S),25-EC
showed that both can activate the HH pathway in a dose-depen-
dent manner (Figures 1E–1H). Moreover, 7b,27-DHC and
24(S),25-EC synergized with one another to activate the HH
pathway, suggesting that cilia-associatedoxysterolsmayactivate
the HH pathway through multiple effectors or multiple domains
within a single effector (Figure 1I).
Synthetic oxysterols and cholesterol require the SMO CRD to
activate the HH pathway (Huang et al., 2016; Luchetti et al.,
2016; Myers et al., 2013). To determine whether the SMO CRD
is also necessary for cilia-associated oxysterols to activate the
HH pathway, we co-transfected ciliated Smo/ mouse embry-
onic fibroblasts (MEFs) with a HH pathway luciferase reporter
and SMO or SMO lacking the CRD (SMODCRD) and treated
the cells with vehicle, 7b,27-DHC, 24k-C, or 24(S),25-EC. Similarto synthetic oxysterols and cholesterol, 7b,27-DHC was unable
to activate the HH pathway through SMODCRD (Figure 1J).
In contrast, 24k-C and 24(S),25-EC were able to activate
the pathway through SMODCRD, albeit to a reduced extent,
suggesting that these two oxysterols can function indepen-
dently of the CRD through another domain of SMO (Figure 1K).
Similar to 24k-C and 24(S),25-EC, Sonic Hedgehog (SHH) acti-
vated the HH pathway through SMODCRD to a reduced extent
(Figure 1J). Together, these data indicate that 7b,27-DHC,
24k-C, and 24(S),25-EC are cilia-associated oxysterols capable
of activating SMO.
To test whether any cilia-associated oxysterols promote the
accumulation of SMO in cilia, we generated NIH/3T3 cell lines
stably expressing EGFP fusions of wild-type SMO or SMO with
the Y134F substitution (SMOY134F), which abolishes oxysterol
interaction with the CRD (Nachtergaele et al., 2013). Quantifica-
tion of ciliary immunofluorescence revealed that 7b,27-DHC,
which requires the CRD to activate the HH pathway (Figure 1J),
and 24(S),25-EC, which does not require the CRD (Figure 1K),
both inducedaccumulationofSMO-EGFP incilia (Figures1L, 1M,
and S2A). 7b,27-DHC did not cause SMOY134F-EGFP to accu-
mulate in cilia (Figures 1L and S2A). In contrast, 24(S),25-EC
caused SMOY134F-EGFP to accumulate in cilia, consistent with
the ability of this oxysterol to activate the HH pathway indepen-
dent of the SMO CRD (Figures 1M and S2A). Thus, 7b,27-DHC
and 24(S),25-EC are oxysterols that are present in cilia and can
promote the accumulation of SMO in cilia and activation of the
HH pathway through distinct mechanisms.
Cilia-Associated Oxysterols Activate the HH Pathway
through Separate SMO Domains
Although theSMOCRD is critical for 7b,27-DHC to activate SMO,
the dispensability of the CRD for SMO activation by 24k-C and
24(S),25-EC raises the possibility that other domains of SMO
may interact with oxysterols. Apart from the CRD, vertebrate
SMO contains a site within the transmembrane domains of the
heptahelical bundle (HHB) that binds small molecules, such as
cyclopamine (CYA) (Chen et al., 2002a, 2002b). In addition,
certain B-ring oxysterols can inhibit SMO at a site distinct from
either the CRD or the HHB (Chen et al., 2002a; Sever et al.,
2016), raising the possibility that there is another site within
SMO that interacts with 24k-C and 24(S),25-EC.
To probe whether a cilia-associated oxysterol can bind to a
domain of SMO other than the CRD, we synthesized 24k-C-
BODIPY (Figure S2B) and assessed its ability to interact with re-
combinant SMO or SMODCRD by fluorescence polarization
anisotropy. Either SMO or SMODCRD increased the polarization
of CYA-BODIPY fluorescence, consistent with the ability of
CYA to interact with either the CRD or the HHB (Figure 2A;
Chen et al., 2002a; Huang et al., 2016). Consistently, CYA-
BODIPY demonstrated positively cooperative binding to SMO
(Hill coefficient 1.6), but not to SMODCRD (Hill coefficient 0.8),
and the micromolar Kd of CYA-BODIPY binding to SMO was
four-fold lower than to SMODCRD (Byrne et al., 2016; Chen
et al., 2002a). Like CYA-BODIPY fluorescence polarization,
24k-C-BODIPY fluorescence polarization increased in the
presence of SMO (Figure 2B). 24k-C-BODIPY fluorescence po-
larization also increased in the presence of SMODCRD with aMolecular Cell 72, 316–327, October 18, 2018 317
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Figure 1. Cilia Contain Oxysterols that Bind the SMO CRD, Activate the HH Pathway, and Cause SMO to Accumulate in Cilia
(A) Immunofluorescence of a sea urchin embryo stained for cilia (acetylated tubulin [TubAc], red) and nuclei (DAPI, blue). The scale bar represents 10 mm.
(B) Immunoblot of lysates from sea urchin cilia, de-ciliated embryos, and whole sea urchin embryos. The ciliary fraction is enriched for TubAc and does not contain
detectable components of the cytoplasm (b-actin).
(C) HPLC-MS/MS quantitation of oxysterols extracted from de-ciliated sea urchin embryos (black) and isolated cilia (green). Data are normalized to protein
concentration and plotted relative to oxysterol levels in whole embryos (dashed line). 7k-C, 7b,27-DHC, 24k-C, and 24(S),25-EC are enriched in sea urchin
embryo cilia.
(D) Anti-Myc immunoblot of detergent-solubilized membranes from HEK293S cells expressing SMO-Myc and incubated with 20(S)-yne affinity resin in the
presence of 50 mM 20(S)-OHC, 7b,27-DHC, or 24(S),25-EC in ethanol. 20(S)-OHC, 7b,27-DHC, and 24(S),25-EC all interfere with the binding of SMO-Myc to
20(S)-yne affinity resin, indicating that they bind the CRD.
(E–H) qRT-PCR assessment of Gli1 (E and G) and Ptch1 (F and H) expression by ciliated NIH/3T3 cells treated with vehicle (ethanol), 100 nM SAG, 7b,27-DHC
(E and F), or 24(S),25-EC (G and H). Data are normalized to vehicle control. 7b,27-DHC and 24(S),25-EC activate the HH pathway in a dose-dependent manner.
(I) qRT-PCR assessment of Gli1 expression by ciliated NIH/3T3 cells treated with vehicle (ethanol), 10 mM 7b,27-DHC, 10 mM 24(S),25-EC, or both. Data are
normalized to vehicle control. 7b,27-DHC and 24(S),25-EC synergistically activate the HH pathway.
(J) Luciferase activity in ciliated Smo/ MEFs co-transfected with Gli-luciferase reporter and empty vector (EV), SMO, or SMODCRD and treated with vehicle
(ethanol), SHHN conditioned media, 10 nm SAG1.5, or ethanol complexed with 30 mM 7b,27-DHC. Data are normalized to activity in cells expressing SMO and
treated with vehicle control. 7b,27-DHC requires the CRD to activate the HH pathway.
(K) Luciferase activity in ciliated Smo/MEFs co-transfected with Gli-luciferase reporter and EV, SMO, or SMODCRD and treated with vehicle (1 mMMbCD) or
MbCD complexed with 30 mM cilia-associated oxysterols. Data are normalized to activity in cells expressing SMO and treated with vehicle control. 24k-C
and 24(S),25-EC do not require the CRD to activate the HH pathway.
(L and M) Ciliary fluorescence intensity from NIH/3T3 cells stably expressing SMO-EGFP or SMOY134F-EGFP and treated with vehicle (ethanol) or 30 mM
7b,27-OHC (L) or 24(S),25-EC (M). Data are from 2 separate stable cell lines normalized to the average ciliary intensity of SMO-EGFP of cells treated with vehicle.
Cilia-associated oxysterols induce SMO accumulation in cilia. Y134F substitution in the CRD blocks the effect of 7b,27-OHC, but not 24(S),25-EC, on ciliary
accumulation, further suggesting that 24(S),25-EC can activate SMO independently of the CRD.
Histogram error bars show SEM. *p% 0.05; Student’s t test. See also Figures S1 and S2A.
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Figure 2. Cilia-Associated Oxysterols and the SMOM2 Substitution Function through the CBP
(A andB) Florescence polarization anisotropy of human SMOandSMODCRD in response to 20 nMCYA-BODIPY (A) or 50 nM24k-C-BODIPY (B). Data are shown
in a.u. CYA-BODIPY binding to SMO is positively cooperative (Hill coefficient 1.6) with higher affinity than to SMODCRD (Hill coefficient 0.8). 24k-C-BODIPY binds
to SMO and SMODCRD (Hill coefficients 1) with equivalent affinities.
(C) Schematic of SMO with relative positions of CRD (red) and a predicted oxysterol binding pocket at the membrane-proximal cytoplasmic surface (CBP, aqua)
within the HHB (gray). The C-terminal domain (CTD) is also depicted in gray. Residue numbers demarcating domains are indicated.
(D–F) Docking of 24k-C and 24(S),25-EC against human SMO (PDB: 5L7D) predicts oxysterol binding to the CBP (graymesh encompasses residues in aqua). The
CBP is composed of intracellular loops and portions of transmembrane domains (TMDs) 1 (T251-I266), 3 (W339-L346), 6 (N446-I454), and 7 (W535-T553) and is
(legend continued on next page)
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Kd equivalent to that for full-length SMO, indicating that 24k-C-
BODIPY can bind to a domain of SMO other than the CRD.
To identify possible oxysterol binding sites outside of the CRD,
wecomputationally docked theoxysterols24k-Cand24(S),25-EC
in human SMOwith 4A˚ relaxation of side chains tomimic induced
fit. We identified a possible binding pocket comprised of cyto-
plasmic-facing portions of transmembrane domain 1 (TMD1)
(T251-I266), TMD3 (W339-L346), TMD6 (N446-I454), and TMD7
(W535-T553; Figures 2C and 2D). We named this site the cyto-
plasmic binding pocket (CBP). Within the CBP, modeling
suggested that residues D255 and N446 in human SMO (corre-
sponding to D259 and N450 in mouse SMO) could hydrogen
bond with the carbon 3 hydroxyl and iso-octyl tail oxygens of
24k-C and 24(S),25-EC, respectively (Figures 2E and 2F). There-
fore, we hypothesized that 24k-C and 24(S),25-EC activate SMO
by binding to the CBP.
To test whether the CBP participates in oxysterol-mediated
activation of SMO, we generatedmutant forms of SMOwith sub-
stitutions at either of the two residues predicted to hydrogen
bond with oxysterols (D259R or N450D; Figure S2C). We trans-
fected ciliated Smo/ MEFs with wild-type SMO, SMOY134F,
SMOD259R, or SMON450D; stimulated the HH pathway by adding
SAG, SHH, 7b,27-DHC, or 24(S),25-EC; and assessed HH
pathway activity. SAG activated wild-type and mutant SMO,
although mutants showed decreased activity (Figures 2G and
S2D). 7b,27-DHC activated SMOD259R and SMON450D equiva-
lently to SAG but activated SMOY134F less than SAG, providing
additional evidence that 7b,27-DHC functions through the CRD
(Figure 2G). In contrast, 24(S),25-EC activation of SMOY134F,
SMOD259R, and SMON450D was less than wild-type SMO, sug-
gesting that activation by 24(S),25-EC involves both the CRD
and the CBP (Figure 2G). Further supporting the idea that the
CRD and CBP have partly overlapping functions in promoting
SMO activity, neither 7b,27-DHC nor 24(S),25-EC could activate
SMO containing substitutions in both the CRD and CBP
(SMOY134F, D259R; Figure 2G). These data suggest that cilia-asso-
ciated oxysterols activate SMO through both the CRD and CBP.
Todeterminewhether theCBP regulates accumulation of SMO
in cilia, we generated additional NIH/3T3 lines stably expressingdistant from the CRD (red). Residues D255 and N446 (corresponding to D259 and
the carbon 3 hydroxyl and iso-octyl tail oxygens, respectively, of 24k-C (E) and 2
(G) qRT-PCR assessment of Gli1 expression in ciliated Smo/ MEFs expressing
and treated with vehicle (ethanol), 100 nM SAG, or 30 mM 7b,27-DHC or 24(S),25-
treated with vehicle. Y134F substitution in the CRD attenuates the ability of 7b,27-
in the CBP attenuate the effect of 24(S),25-EC. Combined substitutions in the CR
effect of SAG.
(H) Ciliary fluorescence intensity of NIH/3T3 cells stably expressing mouse SMO
vehicle (ethanol), 100 nM SAG, 1 mg/mL SHH, or 30 mM 7b,27-DHC or 24(S),25-EC
expressing wild-type SMO-EGFP and treated with vehicle. Y134F substitution i
mulation in cilia, whereas the D259R and N450D substitutions in the CBP block t
effect of cilia-associated oxysterols and SHH and substantially attenuate the effe
(I) Docking of 24(S),25-EC against human SMO predicts van der Waals interac
mutated in SMOM2. Interaction lengths are shown in A˚.
(J) Luciferase activity of ciliated Smo/MEFs co-transfected withGli-luciferase r
SMOM2Y134F, SMOM2D259R, or SMOM2Y134F, D259R. Data are normalized to SMO
combined substitutions in the CRD and CBP inhibit the activity of SMOM2.
(K) Ciliary fluorescence intensity of NIH/3T3 cells stably expressing mouse SMOM
to the average ciliary intensity of cells expressing SMOM2-EGFP. Combined sub
Histogram error bars show SEM. *p% 0.05; Student’s t test. See also Figures S
320 Molecular Cell 72, 316–327, October 18, 2018EGFP fusions of SMOD259R, SMON450D, and SMOY134F, D259R
(Figure S2C). Quantitative immunofluorescence showed that
SHH and SAG caused SMOY134F-EGFP, SMOD259R-EGFP, and
SMON450D-EGFP to accumulate in cilia, although to a lesser
extent than wild-type SMO-EGFP (Figure 2H). 7b,27-DHC
caused SMOD259R-EGFP and SMON450D-EGFP to accumulate
in cilia, but not SMOY134F-EGFP, again consistent with 7b,27-
DHC requiring the CRD to activate the HH pathway (Figure 2H).
In contrast, 24(S),25-EC failed to induce ciliary accumulation of
either SMOD259R-EGFP or SMON450D-EGFP but did cause
SMOY134F-EGFP to accumulate in cilia, further suggesting that
24(S),25-EC activity is dependent on the CBP (Figure 2H).
Combining substitutions that inhibit the function of both the
CRD and theCBP (SMOY134F, D259R) abolished the ability of either
7b,27-DHC or 24(S),25-EC to promote ciliary accumulation (Fig-
ure 2H). Together, these results suggest that 7b,27-DHC acts
through the CRD, 24(S),25-EC primarily acts through the CBP,
and the CRD and CBP have overlapping functions in promoting
the ciliary accumulation of SMO in cilia. In further support of
that hypothesis, ciliary accumulation of SMOD259R-EGFP,
SMON450D-EGFP, and SMOY134F-EGFP by SHH and SAG were
diminished, and SHH failed to cause SMOY134F, D259R-EGFP to
accumulate in cilia (Figure 2H).
SMOW535L, also called SMOM2, is a constitutively active,
oncogenic form of SMO associated with HH pathway-associ-
ated medulloblastoma and basal cell carcinoma (Lam et al.,
1999; Xie et al., 1998). How the W535L substitution activates
SMO is unknown. We discovered that W535 is located within
the CBP, and modeling suggested that W535 may form van
der Waals interactions with oxysterols (Figure 2I). To determine
whether residues involved in oxysterol binding are necessary
for SMOM2 activity, we expressed SMOM2, SMOM2Y134F,
SMOM2D259R, or SMOM2Y134F, D259R in ciliated Smo/ MEFs.
Y134F and D259R substitutions reduced SMOM2 activity, and
combined Y134F and D259R substitutions blocked SMOM2
activity, suggesting that the CRD and CBP are both important
for oncogenic HH signaling by SMOM2 (Figures 2J and S2D).
To determine whether the CRD and CBP are important for
ciliary accumulation of SMOM2, we generated stable NIH/3T3N450 in mouse SMO) are predicted to form hydrogen bonds (dashed lines) with
4(S),25-EC (F). Hydrogen bond lengths are shown in angstroms (A˚).
wild-type mouse SMO, SMOY134F, SMOD259R, SMON450D, or SMOY134F, D259R
EC. Data are normalized to Gli1 expression in wild-type SMO-expressing cells
DHC and 24(S),25-EC to induceGli1, whereas D259R and N450D substitutions
D and CBP block the effects of cilia-associated oxysterols and attenuate the
-, SMOY134F-, SMOD259R-, SMON450D -, or SMOY134F, D259R-EGFP treated with
. Data are from 2 separate cell lines normalized to the average intensity in cells
n the CRD specifically blocks the ability of 7b,27-DHC to induce SMO accu-
he effect 24(S),25-EC. Combined substitutions in the CRD and CBP block the
ct of SAG.
tions between cilia-associated oxysterols and W535 of the CBP, the residue
eporter and oncogenic constitutively active form of SMO, SMOM2 (SMOW535L),
M2 activity. Y134F substitution in the CRD, D259R substitution in the CBP, and
2- or SMOM2Y134F, D259R-EGFP. Data are from 2 separate cell lines normalized
stitutions in the CRD and CBP block SMOM2 accumulation in cilia.
2B–S2E.
lines expressing fusions of EGFP with SMOM2 or SMOM2 with
combined Y134F and D259R substitutions. Consistent with the
functional data, quantitative immunofluorescence showed that
SMOM2Y134F, D259R-EGFP failed to accumulate in cilia, indicating
that the CRD and CBP are critical for mediating the constitutive
ciliary localization of SMOM2 (Figures 2K and S2E). Thus, as with
wild-type SMO, the CRD andCBP promote the ability of SMOM2
to activate the HH pathway.
The Oxysterol Synthase HSD11b2 Participates in SMO-
Mediated Activation of the HH Pathway
We hypothesized that enzymes involved in cilia-associated oxy-
sterol biosynthesis would be enriched in domains of active HH
signaling. To begin to test that hypothesis, we performed RNA
sequencing of the mouse Math1-Cre SmoM2c/WT model of
HH-pathway-associated medulloblastoma, in which constitu-
tively active SMOM2 is specifically expressed in the cerebellar
external granule layer (EGL). Among the diverse oxysterol syn-
thases expressed in medulloblastoma, hydroxysteroid 11-b de-
hydrogenase 2 (Hsd11b2) displayed the highest differential
expression and was 864- ± 82-fold higher in Math1-Cre
SmoM2c/WT medulloblastomas than in control cerebella (Fig-
ures 3A, S3A, and S3B). Similar to mouse medulloblastoma,
HSD11b2 was also enriched in human HH pathway-associated
medulloblastoma (Figures 3B, S3C, and S3D).
During development, HSD11b2 is expressed in domains of
active HH signaling, including the EGL (Heine and Rowitch,
2009; Na´ray-Fejes-To´th and Fejes-To´th, 2007). Given the devel-
opmental expression pattern of HSD11b2, and the finding that
HSD11b2 is dramatically upregulated in HH pathway-associated
medulloblastoma, we hypothesized that HSD11b2 could partic-
ipate in the production of SMO-activating oxysterols.
PTCH1 represses the HH pathway upstream of SMO, whereas
SUFU represses the HH pathway by binding to GLI transcription
factors downstream of SMO (Briscoe and The´rond, 2013). Sterol
depletion blocked HH pathway activity in ciliated Ptch1/MEFs
but had no effect in ciliated Sufu/MEFs, consistent with a role
for sterols downstream of PTCH1 and upstream of SUFU (Fig-
ure 3C). To test the hypothesis that HSD11b2 potentiates HH
pathway induction, we depleted HSD11b2 using short hairpin
RNAs (shRNAs) in ciliated Ptch1/ and Sufu/ MEFs (Fig-
ure S3E). Like sterol depletion, depleting HSD11b2 attenuated
HH signaling in Ptch1/MEFs, but not Sufu/MEFs, suggest-
ing that HSD11b2 modulates HH signaling downstream of
PTCH1 and upstream of SUFU (Figures 3D and 3E).
HSD11b2 is inhibited by a compound in licorice (Farese et al.,
1991;Monder et al., 1989). We hypothesized that carbenoxolone
(CNX), a derivative of the HSD11b2 inhibitor in licorice, would
block HH signaling by inhibiting oxysterol production. In support
of that hypothesis, we found that CNX reduced HH pathway
activity in a dose-dependent manner in Ptch1/ MEFs, but
not Sufu/ MEFs (Figures 3F and 3G).
To determine whether HSD11b2 regulates SMO, we ex-
pressed SMO or SMODCRD in ciliated Smo/ MEFs, stimu-
lated with SHH with or without HSD11b2 inhibition, and
measured pathway activity. CNX inhibition of HSD11b2 reduced
HH signaling through SMObut had no effect on signaling through
SMODCRD, suggesting that HSD11b2 promotes the productionof oxysterols that act through the CRD (Figure 3H). Competition
assays with BODIPY-CYA demonstrated that CNX does not
directly antagonize SMO at the CYA-binding pocket (Fig-
ures S3G and S3H).
Given that cilia-associated oxysterols can bind the CRD and
induce SMO accumulation in cilia, we hypothesized that
HSD11b2 would also regulate SMO accumulation in cilia.
Indeed, in NIH/3T3 cells stimulated with either SHH or SAG,
pharmacologic inhibition of HSD11b2 reduced the ciliary accu-
mulation of SMO (Figures 3J, 3K, and S3F). Together, these
data indicate that HH signaling induces expression of
HSD11b2, which promotes SMO activity through production of
oxysterols that act at the CRD (Figure 3L).
HSD11b2 and CYP27A1 Participate in the Production of
SMO-Activating Oxysterols
Overexpression of HSD11b2 in ciliated NIH/3T3 cells conferred
resistance to CNX but did not activate the HH pathway (Fig-
ures S3I and S3J). One interpretation of these data is that
HSD11b2 generates a precursor molecule that requires down-
stream processing by a rate-limiting enzyme to activate SMO.
7k-C is present in sea urchin embryo cilia (Figure 1C), and we
hypothesized that HSD11b2 converts 7b-OHC to 7k-C as a pre-
cursor for biosynthesis of 7-keto,27-hydroxycholesterol (7k,27-
OHC) and 7b,27-DHC, both of which bind to SMO and promote
SMO activity (Myers et al., 2013) (Figure 4A). To test whether
HSD11b2 can generate 7k-C, we cultured HEK293T cells over-
expressing HSD11b2 with 7b-OHC or the related oxysterol
7a-OHC and used HPLC-MS/MS to assess 7k-C production.
HSD11b2 increased 7k-C production in 7b-OHC-treated cells,
but not in 7a-OHC-treated cells (Figure 4B). 7k-C production in
HEK293T cells overexpressing HSD11b2 was inhibited by CNX
(Figure 4B), suggesting that HSD11b2 converts 7b-OHC to 7k-C.
To assess whether HSD11b2 participates in the production of
cilia-associated oxysterols, we biochemically isolated cilia from
pig (Sus scrofa) LLC-PK1 renal cells (Figures 4C and 4D), which
express Hsd11b2 (Figure S3K). HPLC-MS/MS analysis revealed
that LLC-PK1 cilia, like sea urchin cilia, were enriched in 7k-C
(Figures 4E, S1C, and S1D). Pharmacologic inhibition of
HSD11b2 reduced 7k-C in LLC-PK1 cells and cilia (Figure 4E),
further indicating that HSD11b2 generates 7k-C.
To test the hypothesis that HSD11b2 converts 7b-OHC to
7k-C as a precursor for the biosynthesis of SMO-activating oxy-
sterols, we cultured ciliated Ptch1/ MEFs in oxysterols and
Hsd11b2 shRNAs or CNX. Following genetic or pharmacologic
inhibition of HSD11b2, the addition of 7k-C, 7b,27-DHC, and
7k,27-OHC restored HH pathway activity (Figures 4F, 4G, and
S3L). Thus, 7k-C, 7b,27-DHC, and 7k,27-OHC function down-
stream of HSD11b2 to activate the HH pathway.
Sterol 27-hydroxylase (CYP27A1) converts 7k-C into 7k,27-
OHC (Figure 4H; Heo et al., 2011), and we hypothesized that
CYP27A1 acts downstream of HSD11b2 to generate SMO-acti-
vating oxysterols. LLC-PK1 cells do not transduce HH signals
and do not express Cyp27a1 (Figure S3K). However, expression
of CYP27A1 in LLC-PK1 cells was sufficient to activate the HH
transcriptional program, suggesting that absence of CYP27A1
limits the production of a SMO-activating oxysterol in LLC-PK1
cells (Figure 4I). Like HSD11b2, shRNA-mediated depletion ofMolecular Cell 72, 316–327, October 18, 2018 321
A B C D E F
G H I J K L
Figure 3. HSD11b2 Promotes HH Pathway Activation and Causes SMO to Accumulate in Cilia in a Manner that Requires the CRD
(A) RNA sequencing of medulloblastomas from P35 Math1-Cre SmoM2c/WT mice compared to control cerebella of P35 SmoM2c/WT littermates indicates that
Hsd11b2 expression is 864- ± 82-fold higher in HH pathway-associated medulloblastoma.
(B) Re-analysis of human transcriptome data SPR008292 indicates that HSD11b2 expression is highest in HH pathway-associated medulloblastoma. Data are
shown in a.u.
(C) qRT-PCR assessment of Gli1 expression in ciliated Ptch1/ and Sufu/ MEFs treated with vehicle (water) or 1% MbCD and 20 mM pravastatin to deplete
sterols. Data are normalized to vehicle treatment. Sterol depletion inhibits HH pathway activation caused by loss of PTCH1, but not loss of SUFU, consistent with
a critical role for sterols in SMO activation.
(D) qRT-PCR assessment of Hsd11b2 and Gli1 expression in ciliated Ptch1/ MEFs transduced with 1 of 2 different Hsd11b2 shRNAs. Data are normalized to
expression in scrambled shRNA control-transduced cells. Hsd11b2 knockdown (KD) inhibits HH pathway activation downstream of PTCH1.
(E) qRT-PCR assessment of Hsd11b2 and Gli1 expression in ciliated Sufu/ MEFs transduced with Hsd11b2 shRNAs. Data are normalized to expression in
scrambled shRNA control-transduced cells.Hsd11b2 KD does not inhibit HH pathway activation caused by loss of SUFU, consistent with HSD11b2 acting at the
level of SMO.
(F) qRT-PCR assessment of Gli1 expression in ciliated Ptch1/MEFs treated with vehicle (water) or CNX. Data are normalized to expression in vehicle-treated
cells. Pharmacologic inhibition of HSD11b2 inhibits HH signaling downstream of PTCH1 in a dose-dependent manner.
(G) qRT-PCR assessment of Gli1 expression in ciliated Sufu/ MEFs treated with vehicle (water) or 400 nM CNX. Data are normalized to expression in vehicle-
treated cells. Pharmacologic inhibition of HSD11b2 does not inhibit HH pathway activation caused by loss of SUFU.
(H) Luciferase activity of ciliated Smo/ MEFs co-transfected with Gli-luciferase reporter and SMO or SMODCRD and treated with vehicle (water) or 1 mg/mL
SHH, with or without 400 nM CNX. Data are normalized to luciferase activity of SMO-expressing cells treated with vehicle. The CRD is required for CNX to
block HH pathway stimulation by SHH.
(I) qRT-PCR assessment ofGli1 expression in ciliated NIH/3T3 cells treated with vehicle (water), 1 mg/mL SHH, or 100 nM SAG, with or without 400 nMCNX. Data
are normalized to expression in vehicle-treated cells. Pharmacologic inhibition of HSD11b2 blocks HH pathway stimulation by SHH or SAG.
(J) Immunofluorescence of endogenous SMO (red) localization to cilia (ARL13B, green) in NIH/3T3 cells treatedwith vehicle (water), 1 mg/mLSHH, or 100 nMSAG,
with or without 400 nM CNX. The scale bar represents 1 mm.
(K) Quantitation of SMO ciliary immunofluorescence normalized to intensity in vehicle-treated cells. Pharmacologic inhibition of HSD11b2 blocks SMO accu-
mulation in cilia by SHH or SAG.
(L) Model of the HSD11b2-mediated HH pathway activation. Pathway activators are shown in green. Pathway inhibitors are shown in red.
Histogram error bars show SEM. *p% 0.05; Student’s t test. See also Figure S3.CYP27A1 inhibited HH pathway activity in Ptch1/ MEFs (Fig-
ures 4J and S3M). 7b,27-DHC and 7k,27-OHC, but not 7k-C,
restored HH signaling following depletion of CYP27A1 (Fig-
ure 4J). Thus, CYP27A1 functions downstream of 7k-C in the
pathway of SMO-activating oxysterol biosynthesis. A model
that accounts for these data is that (1) HSD11b2 oxidizes
7b-OHC to 7k-C, (2) CYP27A1 oxidizes 7k-C to 7k,27-OHC,
and (3) reactive oxygen species reduce 7k,27-OHC to 7b,27-
DHC (Figure 4K). Both 7k,27-OHC and 7b,27-DHC bind to the322 Molecular Cell 72, 316–327, October 18, 2018CRD, cause SMO to accumulate in cilia, and induce HH pathway
activity.
Oxysterol Biosynthesis Potentiates Cerebellar and
Oncogenic HH Signaling
Hsd11b2 is strongly expressed in the neonatal cerebellum,
raising the possibility that it participates in cerebellar develop-
ment (Figure 5A; Pal et al., 2011). To test that hypothesis, we
conditionally deleted Hsd11b2 (Hsd11b2c/c; Jiang et al., 2013)
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Figure 4. HSD11b2 and CYP27A1 Participate in the Biosynthesis of
SMO-Activating Oxysterols
(A) Anti-Myc immunoblot of detergent-solubilized membranes from HEK293S
cells expressing Myc-tagged SMO and incubated with 20(S)-yne affinity resin
in the presence of 50 mM of the indicated oxysterols. 7b,27-DHC and 7k,27-
OHC, but not 7k-C, compete for occupancy of 20(S)-yne affinity resin, indi-
cating that 7b,27-DHC and 7k,27-OHC bind the CRD.
(B) HPLC-MS/MS measurement of 7k-C in HEK293T cells transfected with
empty vector or expressing HSD11b2 and incubated with vehicle (ethanol) or
10 mM 7a-OHC or 7b-OHC, with or without 400 nM CNX. Data are normalized
to deuterated 7k-C internal standards and vehicle-treated cells transfected
with empty vector. HSD11b2 converts 7b-OHC to 7k-C and is inhibited
by CNX.
(C) Immunofluorescence of a primary cilium (ARL13B, green), basal body
(g-tubulin, red), and nucleus (DAPI, blue) of a LLC-PK1 cell. The scale bar
represents 5 mm.
(D) Immunoblot of lysates from LLC-PK1 cells and isolated cilia. The ciliary
fraction is enriched for the ciliary component acetylated tubulin (TubAc) and
does not contain detectable components of the cytoplasm (b-actin) or Golgi
(GM130) or HSD11b2.
(E) HPLC-MS/MS measurement of 7k-C in LLC-PK1 cells and isolated cilia
treated with vehicle (ethanol) or 400 nM CNX. Data are normalized to protein
concentration in each sample relative to 7k-C of cells treated with vehicle.
LLC-PK1 cilia are enriched in 7k-C, and pharmacologic inhibition of HSD11b2
reduces cellular and ciliary 7k-C.
(F) qRT-PCR assessment of Gli1 expression in ciliated Ptch1/ MEFs trans-
duced with scrambled control or Hsd11b2 shRNAs and treated with 1 mM
MbCD vehicle or 30 mM of the indicated oxysterols. Data are normalized to
expression in cells transduced with scrambled shRNA and treated with
vehicle. 7k-C, 7b,27-DHC, and 7k,27-OHC restore HH signaling to Hsd11b2-
depleted cells.
(G) qRT-PCR assessment ofGli1 expression in ciliated Ptch1/MEFs treated
with 1 mMMbCD vehicle, 400 nM CNX, and 30 mMof the indicated oxysterols.
Data are normalized to Gli1 expression in vehicle-treated cells. 7k-C, 7b,27-
DHC, and 7k,27-OHC restore HH signaling after pharmacologic inhibition of
HSD11b2.
(H) HPLC-MS/MS measurement of 7k,27-OHC in HEK293S cells transfected
with empty vector or expressing CYP27A1 and incubated with vehicle
(ethanol) or 10 mM7k-C. Data are normalized to deuterated 7k,27-OHC internal
standards and vehicle-treated cells transfected with empty vector. CYP27A1
converts 7k-C to 7k,27-OHC.
(I) Luciferase activity of ciliated LLC-PK1 cells co-transfected with Gli-lucif-
erase reporter and empty vector or CYP27A1. Data are normalized to activity in
empty vector transfected cells. CYP27A1 expression in LLC-PK1 cells is
sufficient to activate HH pathway activity.
(J) qRT-PCR assessment of Gli1 expression in ciliated Ptch1/ MEFs trans-
duced with scrambled control or Cyp27a1 shRNAs and treated with 1 mM
MbCD vehicle or 30 mM of the indicated oxysterols. Data are normalized to
expression in cells transduced with scrambled shRNA and treated with
vehicle. 7b,27-DHC and 7k,27-OHC, but not 7k-C, restore HH pathway activity
in Cyp27a1-depleted cells.
(K) Model of the biosynthesis of SMO-activating oxysterols.
Histogram error bars show SEM. *p% 0.05; Student’s t test. See also Figures
S1 and S3.in the EGL usingMath1-Cre and found thatMath1-Cre Hsd11bc/c
mice are subviable (p = 0.01; chi-square test). HH signaling pro-
motes EGL proliferation (Corrales et al., 2006), and in mice sur-
viving to P7, deletion of Hsd11b2 decreased EGL thickness
and reduced cerebellar HH pathway activity (Figures 5B–5D).
Using HPLC-MS/MS and SmoM2c/WT cerebella, we found
that 7k-C was elevated at P14, when the cerebellum is still
developing (Figures 5E and S4). At P35, cerebellar 7k-C
decreased, paralleling decreased Hsd11b2 expression (Figures
5A and 5E). Constitutive HH pathway activation in the EGL ofMolecular Cell 72, 316–327, October 18, 2018 323
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Figure 5. HSD11b2 Promotes Developmental and Oncogenic HH
Signaling
(A) Re-analysis of mouse transcriptome data GSE23525 indicates that cere-
bellar Hsd11b2 expression decreases from birth to postnatal day 56. In
contrast, cerebellar Cyp27a1 expression remains largely stable. Data are
shown as percent of nadir.
(B) H&E-stained micrographs of P7 control Hsd11b2c/c and Math1-Cre
Hsd11b2c/c cerebella. The scale bar represents 30 mm.
(C) Quantitation of EGL thickness in Hsd11 b2c/c and Math1-Cre Hsd11b2c/c
cerebella. Homozygous genetic deletion of Hsd11b2 restricts EGL growth.
(D) qRT-PCR assessment of Gli1 expression in P7 control Hsd11b2c/c and
Math1-Cre Hsd11b2c/c cerebella. Data are normalized to expression in control
cerebella. Homozygous deletion of Hsd11b2 attenuates HH pathway activity
during cerebellar development.
(E) HPLC-MS/MS measurement of 7k-C in control SmoM2c/WT and Ptch1c/c
cerebella during development (P14) and/or adulthood (P35) as compared to
Math1-Cre SmoM2c/WT and Math1-Cre Ptch1c/c medulloblastomas. 7k-C
levels are normalized to sample weights. 7k-C levels are elevated at P14
cerebella and in HH-pathway-associated medulloblastoma.
(F) qRT-PCR assessment of Gli1 expression in P35 control SmoM2c/WT
cerebella and Math1-Cre SmoM2c/WT, Math1-Cre SmoM2c/WT Hsd11b2c/WT,
and Math1-Cre SmoM2c/WT Hsd11b2c/c medulloblastomas. Data are normal-
ized to expression in control cerebella. Homozygous deletion of Hsd11b2 at-
tenuates HH pathway activity in medulloblastoma.
(G) Weight of P35 control SmoM2c/WT cerebella and Math1-Cre SmoM2c/WT,
Math1-Cre SmoM2c/WT Hsd11b2c/WT, andMath1-Cre SmoM2c/WT Hsd11b2c/c
medulloblastomas normalized to total brain weight. Homozygous deletion of
Hsd11b2 blocks the growth of HH-pathway-associated medulloblastoma
caused by activation of SMO.
(H) Gross images of P35 control SmoM2c/WT, Math1-Cre SmoM2c/WT, and
Math1-Cre SmoM2c/WT Hsd11b2c/c brains. Homozygous deletion of Hsd11b2
attenuates the growth of HH-pathway-associated medulloblastoma caused
by activation of SMO. The scale bar represents 5 mm.
(I) Sagittal H&E-stained sections of P35 control SmoM2c/WT cerebella
and Math1-Cre SmoM2c/WT and Math1-Cre SmoM2c/WT Hsd11b2c/c me-
dulloblastoma. Homozygous deletion of Hsd11b2 reduces the number
of small round blue tumor cells and partially restores cerebellar architec-
ture in HH-pathway-associated medulloblastoma. The scale bar repre-
sents 2 mm.
(J) Kaplan-Meier curves of 27 Math1-Cre SmoM2c/WT and 32 Math1-Cre
SmoM2c/WT Hsd11b2c/cmice. Homozygous deletion of Hsd11b2 prolongs the
survival of mice with HH-pathway-associated medulloblastoma by 25%
(56 days versus 70 days; p < 0.0001; log rank test).
(K) Weight of P21 Ptch1c/c control cerebella and Math1-Cre Ptch1c/c medul-
loblastomas treated with vehicle (water) or 100 mg/g CNX by intraperitoneal
injection for 2 weeks, normalized to total brain weight. Pharmacologic inhibi-
tion of HSD11b2 attenuates the growth of HH-pathway-associated medullo-
blastoma caused by loss of Ptch1.
Histogram error bars show SEM. *p% 0.05; Student’s t test. See also Figures
S4 and S5.
324 Molecular Cell 72, 316–327, October 18, 2018Math1-Cre SmoM2c/WT orMath1-Cre Ptch1c/cmouse models of
HH pathway-associated medulloblastoma increased 7k-C in the
P35 cerebella (Figures 5E and S4), consistent with HH pathway
stimulation of HSD11b2 expression in cerebellar granule cell pre-
cursors (Heine and Rowitch, 2009).
HSD11b2 converts cortisol to cortisone in the kidney, raising
the possibility that HSD11b2 promotes granule cell proliferation
by metabolizing glucocorticoids (Heine and Rowitch, 2009).
However, deletion of HSD11b2 in the cerebellum did not affect
glucocorticoid target gene expression (Figures S5A and S5B),
suggesting that HSD11b2 may not be critical for restraining
physiological levels of glucocorticoids in the cerebellum. In
further contrast to glucocorticoids, pharmacologic inhibition of
HSD11b2 in vivo did not increase medulloblastoma apoptosis
(Figures S5C and S5D).
In support of the possibility that oxysterol synthases produc-
ing SMO-activating ligands participate in pathogenic signaling,
homozygous genetic deletion of Hsd11b2 from the EGL of the
Math1-Cre SmoM2c/WT mice reduced HH pathway activity in
medulloblastoma (Figure 5F). Homozygous genetic deletion of
Hsd11b2 also reduced tumor weight and the prevalence of small
round blue cells characteristic of medulloblastoma, as well as
partially restored cerebellar architecture (Figures 5G–5I). These
changes were associated with prolongation in survival of
Math1-Cre SmoM2c/WT Hsd11b2c/c mice relative to Math1-Cre
SmoM2c/WT animals (70 days versus 56 days; p < 0.0001; log
rank test; Figure 5J).
We hypothesized that, like genetic deletion of Hsd11b2, CNX-
mediated inhibition of HSD11b2 might inhibit the growth of HH
pathway-associated cancer. Treatment of cultured basal cell
carcinoma (ASZ) and medulloblastoma (Med1) cells with CNX
reduced HH pathway activity (Figures S5E and S5F). Mass spec-
trometry confirmed that CNX crosses the blood brain barrier
in vivo (Figure S5G; Heine and Rowitch, 2009). Therefore, we
treated Math1-Cre Ptch1c/c mice with CNX. Similar to homozy-
gous genetic deletion of Hsd11b2 in Math1-Cre SmoM2c/WT
mice, pharmacological inhibition of HSD11b2 reduced tumor
weight and the prevalence of small round blue cells in Math1-
Cre Ptch1c/c medulloblastomas (Figures 5K, S5H, and S5I).
DISCUSSION
We have identified cilia-associated oxysterols that promote
ciliary accumulation of SMO and activate the HH pathway
through two separate domains of SMO. The CRD, an N-terminal
extracellular domain, was previously identified as a site of action
for synthetic oxysterols and cholesterol (Myers et al., 2013;
Nachtergaele et al., 2012, 2013; Nedelcu et al., 2013). The sec-
ond site, the CBP, is at the membrane-cytoplasmic interface,
and like the CRD, substitutions within the CBP abrogate SMO
activity. HSD11b2, an oxysterol synthase expressed in regions
of active HH signaling, participates in the production of SMO-
activating oxysterols that activate the CRD. Consistently, we
find that either genetic deletion of HSD11b2 or pharmacologic in-
hibition with a compound from licorice diminishes HH signal
transduction and the growth of HH pathway-associated cancer.
Recent structures of SMOwith cholesterol or 20(S)-OHC in the
CRD reveal interactions between the 3b-hydroxyl group of ste-
rols and a SMO CRD aspartate (D99 in mouse SMO; Byrne
et al., 2016; Huang et al., 2016, 2018; Luchetti et al., 2016).
SMO D99 is essential for the ability of the CRD to bind sterols,
indicating that CRD binding of the 3b-hydroxyl group of sterols
is important for SMO activation (Huang et al., 2016; Nedelcu
et al., 2013). The 3b-hydroxyl group is also present in cilia-asso-
ciated oxysterols, raising the possibility that cilia-associated
oxysterols bind the CRD in a similar conformation. In the CBP,
modeling and mutagenesis similarly suggest that interaction be-
tween the oxysterol 3b-hydroxyl group and SMO D259 are
important for SMO activation.
Interestingly, W535, commonly mutated to L to oncogenic
activate SMO, is located within the CBP (Xie et al., 1998). Howthe W535L substitution constitutively activates SMOM2 is un-
known. As the activity of SMOM2 depends on other CBP resi-
dues, we speculate that W535L induces a conformational
change that mimics oxysterol binding. In support of the possibil-
ity that SMOM2 does not depend on oxysterol binding to the
CBP, SMOM2 activity is independent of a cholesterol biosyn-
thetic enzyme required for wild-type SMO activity (Blassberg
et al., 2016).
For an oxysterol to be a SMO agonist, it must be present in
HH-responsive cells, it must bind and activate SMO, and it
must be required for pathway activity. We have shown that
7b,27-DHC, 24k-C, and 24,25-EC are produced by sea urchin
and mammalian cells and bind and activate SMO. Moreover,
the contribution of HSD11b2 to oncogenic HH signaling sug-
gests that the oxysterols produced by enzymes are required
for high-level pathway activity, providing evidence that oxyster-
ols are relevant endogenous SMO agonists.
We propose that the SMOCRDandCBP are activated through
binding oxysterols. As SMO-activating oxysterols are enriched in
the ciliary membrane, perhaps SMO only encounters its cognate
oxysterols once it has accessed this specialized compartment.
Alternatively, SMO may encounter oxysterols elsewhere where
they induce a conformation that stimulates SMO accumulation
in cilia. In either model, the involvement of oxysterols activating
SMO through two sites is reminiscent of the ‘‘two-person
concept,’’ which requires two operators to unlock separate locks
to launch a missile, a system designed to increase the fidelity of
critical decisions (Woodward, 2013).
The ability of CNX to suppress medulloblastoma growth sug-
gests that inhibiting oxysterol biosynthesis may be a useful
approach to targeting HH pathway-associated cancers. Given
the selective enrichment of HSD11b2 among molecular sub-
groups of medulloblastoma, we anticipate that oxysterol biosyn-
thesis inhibition may only be useful for HH pathway-associated
tumors. Indeed, the expression of HSD11b2 is highly cell-type-
specific (Heine and Rowitch, 2009; Na´ray-Fejes-To´th and
Fejes-To´th, 2007). Therefore, inhibiting oxysterol synthases
may be a strategy to inhibit the HH pathway in a tissue-specific
manner, thereby lessening the toxicity of HH pathway inhibition
that has limited the clinical utility of SMO antagonists in pediatric
cancer patients (Lucas and Wright, 2016).STAR+METHODS
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METHOD DETAILS
Cell Culture
Med1 cells, and Ptch1/, Smo/ and Sufu/MEFs, were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher
Scientific,Waltham,MA) supplementedwith 10% fetal bovine serum (FBS) and glutamine. NIH/3T3, Flp-IN-3T3 and SHH Light II cells
were cultured similarly except in 10% fetal calf serum. ASZ cells were cultured in 154-CF media (Thermo Fisher Scientific) supple-
mented with glutamine, pen/strep and 4% FBS chelexed to remove calcium (6.7 parts chelexed FBS plus 1 part non-chelexed FBS).
LLC-PK1 cells were cultured in Media 199 (Thermo Fisher Scientific) supplemented with 3% FBS, bicarbonate and glutamine.
To promote ciliogenesis, cell lines other than LLC-PK1 cells were cultured in Opti-MEM (Thermo Fisher Scientific). SHH, SAG, CYA
and vismodegibwere added for 24 hr; glucocorticoids, oxysterols, and sterols were added for 30-36 hr; andCNXwas added for 48 hr.
Chemistry
Reagents and solvents were purchased from Sigma-Aldrich and used as received unless otherwise indicated. A synthetic mecha-
nism is diagramed in Figure S2B. Compound 1 was prepared as previously described (Windsor et al., 2013). Flash column chroma-
tography was carried out using a Biotage Isolera Four system and SiliaSep silica gel cartridges from Silicycle. 1H NMR spectra were
recorded on a Varian INOVA-400 400MHz spectrometer. Chemical shifts are reported in d units (ppm) relative to residual solvent
peak. Coupling constants (J) are reported in hertz (Hz). Characterization data are reported as follows: chemical shift, multiplicity
(s = singlet, d = doublet, t = triplet, m = multiplet), coupling constants, number of protons and mass to charge ratio. LCMS analyses
were performed on a Waters Micromass ZQ/Waters 2795 Separation Module/Waters 2996 Photodiode Array Detector/Waters 2424
Evaporative Light Scattering Detector system.
To synthesize Compound 2 (Figure S2B), a 1 M solution of tetrabutyl ammonium fluoride in tetrahydrofuran (0.126 ml, 0.1 mmol)
was added to a solution of (6R)-6-[(2R,5S,15R)-5-[(tert-butyldimethylsilyl)oxy]-2,15-dimethyltetracyclo[8.7.0.02,7.011,15]heptadec-7-
en-14-yl]hept-1-yn-3-ol (1)(0.045 g, 0.1 mmol) in tetrahydrofuran (1 mL) cooled to 0C. After stirring at room temperature for 18 h, the
reaction mixture was diluted with ethyl acetate and washed with water and brine. The organic layers were dried over magnesium
sulfate, concentrated under reduced pressure and purified by flash column chromatography (0%–50% ethyl acetate/hexanes) to
obtain 31 mg (90%) of Compound 2 as a white solid.
1H NMR (400MHz, CDCl3) mixture of isomers d 5.37-5.39 (m, 1H), 4.35 (t, J = 6.5 Hz, 1H), 3.54-3.56 (m, 1H), 2.49 (t, J = 2.3 Hz, 1H),
2.25-2.31 (m, 2H), 2.00-2.04 (m, 2H), 1.77-1.90 (m, 5H), 1.42-1.65 (m, 12H), 1.10-1.30 (m, 9H), 1.03 (s, 3H), 0.95-0.99 (m, 4H), 0.71
(s, 3H); 13C NMR (100MHz, d6-DMSO) d 140.77, 121.70, 85.03, 72.94, 72.79, 71.82, 62.88, 62.73, 56.76, 55.81, 50.11, 42.35, 42.31,
39.79, 37.26, 36.51, 35.38, 35.36, 34.29, 34.22, 31.91, 31.68, 31.13, 31.01, 28.15, 24.28, 21.09, 19.42, 18.72, 18.67, 11.89; LCMSm/z
407.06 (MNa+).
To synthesize 24k-C-yne (Figure S2B), manganese (IV) oxide, activated (0.13 g, 1.5mmol), was added to a solution of Compound 2
in tetrahydrofuran (2mL) and stirred at room temperature for 48 h. The reactionmixture was filtered through celite, the filtrate concen-
trated under reduced pressure and purified by flash column chromatography (0%–35% ethyl acetate/hexanes) to obtain 9 mg (31%)
of 24k-C-yne as colorless oil.
1H NMR (400MHz, CDCl3) d 5.37 (d, J = 5.1 Hz, 1H), 3.52-3.58 (m, 1H), 3.23 (s, 1H), 2.50-2.67 (m, 2H), 2.22-2.34 (m, 2H), 1.98-2.03
(m, 2H), 1.85-1.88 (m, 4H), 1.47-1.66 (m, 9H), 1.28-1.34 (m, 2H), 0.95-1.21 (m, 10H), 0.70 (s, 3H); 13CNMR (100MHz, CDCl3) d 188.01,
140.76, 121.67, 78.28, 77.24, 71.81, 56.73, 55.74, 50.07, 42.53, 42.41, 42.30, 39.74, 37.26, 36.50, 35.20, 31.90, 31.66, 29.79, 28.11,
24.26, 21.08, 19.41, 18.42, 11.89; LCMS m/z 405.10 (MNa+).
To synthesize 24k-C-BODIPY (Figure S2B), a solution of 0.3 M aqueous solution of copper(II) sulfate pentahydrate (4 mL,
0.0013 mmol) and 1M aqueous solution of sodium ascorbate (26 mL, 0.026) was added to a solution of BODIPY-FL-azide (5 mg,
0.013 mmol) and 24k-C-yne in N,N’-dimethylformamide/water (1 mL, 1:1). After stirring at 80C for 18 h, the reaction mixture
was diluted with dicholoromethane (5 mL). The organic layers were washed with brine, dried over magnesium sulfate, concentrated
under reduced pressure and purified by flash column chromatography (0%–50% ethyl acetate/hexanes followed by 5% methanol/
dichloromethane) to obtain 6 mg (61%) of compound 4 as bright orange solid.Molecular Cell 72, 316–327.e1–e5, October 18, 2018 e2
1H NMR (400 MHz, CDCl3) d 7.11 (s, 1), 6.90 (d, J = 3.9 Hz, 1H), 6.33 (d, J = 3.9 Hz, 1H), 6.17 (s, 1H), 5.38 (d, J = 5.1 Hz, 1H), 4.25
(t, J = 6.9 Hz, 2H), 3.25-3.32 (m, 4H), 3.04-3.15 (m, 2H), 2.73 (t, J = 7.2 Hz, 2H), 2.26-2.31 (m, 4H), 2.02-2.05 (m, 4H), 1.86-1.91 (m, 4H),
1.46-1.54 (m, 16H), 0.98-1.28 (m, 12H), 0.71 (s, 3H); LCMS m/z 757.37 (MH+), 759.39 (MH-).
Cilia Isolation
Gastrula stage Strongylocentrotus purpuratus embryos were concentrated by centrifugation at 170-200 x g for 4-10 min at 4C and
washed 3-4 times with artificial seawater. To isolate cilia, embryos were gently resuspended in 0.5M NaCl in artificial seawater
approximately 10 times the volume of the embryo pellet. The samples were immediately centrifuged at 400 x g for 5 min at 4C to
pellet de-ciliated embryos. The supernatant was transferred to a fresh tube and centrifuged at 400 x g for another 5 min at 4C to
pellet any remaining embryos. The supernatant was then centrifuged at 10,000 x g for 20min at 4C and the cilia pellet was collected.
LLC-PK1 cells were cultured for 3 weeks after confluence for ciliary elongation, and at least three 15-cm diameter plates were
pooled for each treatment condition. Cells were washed in PBS, and cilia were isolated by shear force on a rotary shaker at 37C
for 4min at 360 rotations perminute. Cell debris were removed by centrifugation at 4C for 10min at 1,000 x g, then cilia were isolated
from the supernatant by ultracentrifugation at 4C for 30 min at 40,000 x g (Mitchell, 2013).
Cloning
The Flp-IN-3T3 system was used to stably integrate SMO constructs in pgLAP5 (Thermo Fisher Scientific). pcDNA3.1 (Addgene,
Cambridge, MA) was used for all transient transfections. Site-directed mutagenesis with the QuikChange XL kit (Agilent Technolo-
gies, Santa Clara, CA) was used to introduce substitutions into constructs.
Competition Assays
20(S)-yne affinity resin was prepared and competition experiments were performed as described previously (Myers et al., 2013). For
BODIPY-CYA competition assays, cells were washed in PBS, fixed for 8 min in 4% paraformaldehyde, blocked for 10 min in
Opti-MEMwithout phenol red (Thermo Fisher Scientific) supplemented with 0.5% FBS, and incubated for 1 hr in blocking buffer sup-
plemented with small molecules at room temperature. Coverslips were mounted with Gelvatol mounting media following 2 additional
washes in PBS.
Expression Analysis
RNA sequencing was performed from 3 female Math1-Cre SmoM2c/wt and 3 SmoM2c/wt female P35 littermates. In brief, RNA was
isolated using TRIzol (Thermo Fisher Scientific) followed by RNeasyMini Kit cleanup (QIAGEN, Valencia, CA). Library preparation was
performed using the TruSeq RNA Library Prep Kit v2 (Illumina, San Diego, CA) and sequenced on an Illumina HiSeq 2500 to at least
30million unique reads per sample. Input sequences were analyzed in FASTQ format, with trimming of known adapters and low-qual-
ity regions using Fastq-mcf.; sequence quality control using FastQC and RseQC; alignment to the UCSC mm10 mouse genome
assembly with Bowtie 2.2.4; gene assignment using featureCounts; and Ensembl gene annotation in GTF format (Langmead and
Salzberg, 2012; Liao et al., 2014; Wang et al., 2012). EdgeR was used to calculate differential expression p values, and p.adjust
was used to calculate the false discovery rate for each p value using the Benjamini-Hochberg method (Robinson et al., 2010;
Robinson and Oshlack, 2010; Robinson and Smyth, 2008, 2007).
Fluorescence Polarization Assays
Fluorescence polarization of BODIPY FL conjugated ligands was measured on a Biotek H4 plate reader with 384 well low-volume
microplates. All experiments were equilibrated for 10 to 15 min at room temperature before reading. Samples were excited from
the top using a 485/20 nm filter set for excitation, and a 528/20 nm filter set for the emission. Serial dilutions for binding experiments
were done in protein storage buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 0.03% n-dodecyl-b-D-maltoside [DDM],
0.006% cholesteryl hemisuccinate [CHS]).
Histology and Microscopy
Gross light micrographs were obtained from fresh mouse brains suspended in PBS. For histology, mouse cerebella were fixed over-
night at 4C in 4% paraformaldehyde, washed in PBS, and embedded in paraffin. Sagittal sections were taken through the midline,
and stained with hematoxylin and eosin (H&E) or by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) using the
In Situ Cell Death Detection Kit with Fluorescein (Roche, Basel, CH). Gross and microscopic samples were imaged using an inverted
light microscope (Zeiss, Oberkochen, DE). Fluorescent microscopy was performed on an SP5 confocal microscope (Leica,
Wetzlar, DE). Image processing was completed using ImageJ (Schneider et al., 2012). For fluorescence quantifications, regions of
interest were selected and quantified with normalization to background fluorescence.
Immunoblotting
Immunoblots were performed as described previously (Raleigh et al., 2018). In brief, samples were boiled in 2x Laemmli reducing
buffer for 5 min, separated on 4%–15% gradient TGX precast gels (Bio-Rad), transferred onto nitrocellulose (Whatman, Pittsburgh,
PA) and subjected to immunoblot analysis using ECL Lightening Plus (Perkin-Elmer, Waltham, MA).e3 Molecular Cell 72, 316–327.e1–e5, October 18, 2018
Immunofluorescence
Cells on glass coverslips were washed in PBS and fixed in 4%paraformaldehyde for 8min. Following incubation in blocking buffer for
30min at room temperature (2.5%BSA, 0.1%Triton X-100 and 0.03%NaN3), cellswere incubatedwith primary antibodies in blocking
buffer overnight at 4C. The next day, cells were washed 3 times in PBS and incubated with secondary antibodies and DNA dyes in
blocking buffer at room temperature for 1 hr. Following 3 final washes in PBS, coverslipsweremountedwithGelvatolmountingmedia.
Luciferase Assays
SHH Light II cells stably express a GLI-responsive Firefly luciferase reporter and pRL-TK (Promega, Madison, WI), which constitu-
tively expresses Renilla luciferase. For other cell lines, pRL-TK and reporter constructs were transiently expressed using Lipofect-
amine LTX with Plus Reagent (Thermo Fisher Scientific). HH reporter activity was quantified from pGL3-Luciferase (Promega)
containing 8 consecutive GLI binding sites. Luciferase assays with 1% control renilla construct (5 ng) and 99% reporter luciferase
construct (495 ng) were performed 72 hr after transfection using the Dual Luciferase Reporter Assay System (Promega) and aGloMax
96 Microplate Luminometer with Dual Injectors (Promega). Firefly luciferase reporter activities were calculated relative to internal
renilla luciferase controls.
Mass Spectrometry
For mass spectrometry of sea urchin samples, a modified fractionation method was used to enhance detection of dihydroxysterols
(McDonald et al., 2012). In brief, we used a two-step elution process from the aminopropyl SPE column. Column conditioning, sample
loading, and column rinsing with hexane were all performed as previously described. To elute our compounds of interest, we first
used 2x3mL of 30% diethyl ether in hexane to elute the sterol fraction, followed by 3mL of chloroform/methanol 23:1 to elute the
oxysterol fraction. Separating the cholesterol from the oxysterols allowed us to load more of the oxysterol fraction onto the HPLC
column, enhancing our detection and quantitation of trace-level oxysterols (see Figure S1 for representative chromatograms).
For mass spectrometry of LLC-PK1 and cerebellum samples, oxysterol quantification was performed relative to a d7-7-ketocho-
lesterol (d7-7kC) internal standard that was preapared as previously reported (Xu et al., 2011). The protein content of LLC-PK1 cells
and cilia was determined using the BioRad-DC protein Assay Kit (BioRad, Hercules, CA). The average protein weight of the LLC-PK1
cells and cilia were 5.29 ± 0.62 mg/mL and 0.30 ± 0.09 mg/mL, respectively. Prior to lipid extraction, d7-7k-C internal standard was
added to each sample (150 ng for cells; 25 ng for cilia). Lipid extraction was performed using the Folchmethod, in which 1mL of 0.9%
NaCl and 4mL of Folch solution (2:1 chloroform/methanol) was added to each sample. The resultingmixture was vortexed briefly and
centrifuged at 1000 rpm and 10C for 5 min. The organic layer was recovered and dried under vacuum. The dried extracts were
reconstituted in methylene chloride (300 mL for cells; 200 mL for cilia). For UHPLC-APCI-MS/MS analysis, 100 mL of LLC-PK1 cell
and cilia lipid extracts was transferred into glass LC vials, dried under a stream of Argon, and reconstituted in 90% methanol with
0.1% formic acid (200 mL for LLC-PK1 cells; 50 mL for LLC-PK1 cilia). The cerebellums of P14 and P35 mice were homogenized
in 5 mL of 4:1 Folch/0.9% NaCl with a blade homogenizer in the presence of d7-7k-C internal standard (2 mg for P14; 1 mg for
P35). Following centrifugation, the organic layer was recovered and dried under vacuum. The dried extracts were reconstituted in
1 mL of methylene chloride. For UHPLC-APCI-MS/MS analysis, 50 mL of lipid extract was transferred into glass LC vials, dried under
a stream of Argon and reconstituted in 50 mL of 90% methanol with 0.1% formic acid. Analysis of 7-kC and other oxysterols was
performed by UHPLC-MS/MS on a triple quadrupole mass spectrometer (Sciex 6500) equipped with atmospheric pressure chemical
ionization (APCI), as described previously (Fliesler et al., 2018). Briefly, oxysterols were separated by reversed phase chromatog-
raphy on a C18 column (1.7 mm, 2.13 100 mm, Phenomenex Kinetex) using an isocratic gradient of 90%methanol with 0.1% formic
acid at a flow of 0.4 mL/min. The APCI parameters were as follows: nebulizer current, 3 mA; temperature, 350C; curtain gas, 20 psi;
ion source gas, 55 psi. Selective reaction monitoring (SRM) was used to monitor the dehydration of the oxysterol [M+H]+ ion to
generate [M+H-H2O]
+ ions (d7-7k-C, m/z 408.3/ 390.3; 7k-C, m/z 401.3/ 383.3; 7OH-C, m/z 385.3/ 367.3; 7k,27-OHC, m/z
417.3/ 399.3; 24- or 25-OHC, m/z 385.3/ 367.3; 24k-C and 24,25-EC, m/z 383.3/ 365.3), as described previously (Fliesler
et al., 2018; Xu et al., 2011, 2013) (see Figure S1 for representative chromatograms). The MS conditions for SRM analysis were
as follows: declustering potential, 80 V; entrance potential, 10 V; collision energy, 25 V; collision cell exit potential, 20 V. Data analysis
was performed with Analyst (v. 1.6.2) Quantitation Wizard. Quantitation of each oxysterol was performed against the d7-7k-C internal
standard using a relative response factor (RRF) determined from an equal mixture of each oxysterol and d7-7k-C. The resulting 7k-C
concentration was normalized to either protein content (for LLC-PK1 cells and cilia) or tissue weight (for cerebellums). Sterols, such
as cholesterol and demosterol, were analyzed using a similar LC-MS/MS method as described previously (Fliesler et al., 2018).
Targeted mass spectrometry of oxysterols in HEK293 cells was performed as described previously using deuterated 7k-C and
7k,27-OHC standards (Myers et al., 2013). Targeted mass spectrometry of CNX in mouse brain homogenate used LC-MS/MS in
positive electrospray ionizationmode. Test samples and calibration standards in eachmatrix were processed by protein precipitation
with two volumes of acetonitrile containing 50 ng/mL dextromethorphan internal standard (IS). The precipitated samples were
vortexed, centrifuged at 6,100 x g for 30 min, diluted with two volumes 0.2% formic acid in water, and subsequently analyzed by
LC-MS/MS. The analyte/IS peak area ratios versus the nominal analyte concentrations of the calibration samples in each matrix
were used to fit a calibration curve by power regression. The analyte concentrations for the calibration standards and unknown
samples were calculated using the established calibration equation for each matrix.Molecular Cell 72, 316–327.e1–e5, October 18, 2018 e4
Mice
B6.Cg-Tg(Atoh1-cre)1Bfri/J (Math1-Cre), GT(ROSA)26Sortm1(Smo/EYFP)Amc/J (SmoM2c) and Ptch1tm1Mps/J (Ptch1c) alleles were
obtained from The Jackson Laboratory (Bar Harbor, ME). The Hsd11b2tm1.1Mzz allele was obtained as a generous gift from
Dr. Ming-Zhi Zhang. Animals were monitored for survival until death or protocol-defined neurologic endpoints including hydroceph-
alus or ataxia, and tumor weight was normalized to brain weight. CNX was injected intraperitoneally in water vehicle at 100 mg/g for
14 consecutive days from P7 to P21.
Molecular Modeling
The Small Molecule Drug Discovery Suite 2016-1 was used for the computational modeling (Small-Molecule Drug Discovery
Suite 2016-1: Schro¨dinger Suite 2016-1 Virtua Screening Workflow protocol; LigPrep, version 3.7; Epik, version 3.5, Glide
version 7.0; Prime version 4.3; Schro¨dinger, LLC, New York, NY, 2016.). The protein from PDB 5L7D was prepared in a ready-to-
dock-format with the Protein Preparation Wizard workflow, missing side chains were added, bond orders were assigned, hydrogens
were added and disulfide bonds were created. The orientation of hydroxyl groups and proper protonation state were assigned at
pH 7, using the PROPKA version implemented in Epik version 3.5 (Olsson et al., 2011).
Each small molecule was drawnwith theMaestro graphical user interface version 10.5, and protonation states and tautomers at pH
7.0 ± 2 were predicted by Epik. Three dimensional conformers were assigned using LigPrep version 3.7 together with the OPLS force
field version 3 (Harder et al., 2016). Binding sites in the protein were identified using the SiteMap tool with default parameters resulting
in four sites. Virtual screening was carried out at each site.
For docking, search grids were erected around each of the 4 putative binding pockets with a box size of 20x20x20 A˚3. Small mole-
cule poses were scored using the Glide XP scoring function, and strain energy was included in the energy value. Aromatic groups
were forced to remain planar, and a maximum of 10 poses were identified for subsequent post-docking minimization. Five lowest
energy poses were saved. The best binding poses identified from docking were all located in the cytoplasmic binding pocket
(CBP) composed of residues T251-I266, W339-L346, N446-I454 and W535-T553. These CBP poses were subsequently rescored
with the MM/GBSA protocol (Graves et al., 2008) using the VSGB solvent model and an implicit representation of the membrane.
We allowed protein flexibility up to 4 A˚ from the ligand tomimic induced-fit effects. Themembrane embedded residues used to define
the boundaries of the implicit membrane were determined with the Orientations of Proteins in Membranes (OPM) database (Lomize
et al., 2006).
Quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR)
cDNA was synthesized from tissue and cell culture samples using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). qRT-PCR
primers are described in Table S1. qRT-PCRwas performed with SYBR Green Real-Time PCRMaster Mix (Thermo Fisher Scientific)
and Applied Biosystems (Foster City, CA) and Life Technologies (Grand Island, NY) real-time PCR systems using the DDCt method
relative to GAPDH or b-ACTIN expression.
Reagents
Antibodies and fluorescent molecules were obtained from the following suppliers: TubAc, Sigma-Aldrich (T7451, St. Louis, MO);
Alexa-conjugated secondary antibodies, Life Technologies; ARL13B, Abcam (ab136648, Cambridge, UK); BODIPY-CYA, BioVision
(Milpitas, CA); N3-BODIPY FL, Tocris; b-actin, Abcam (ab8227); DAPI, Thermo Fisher Scientific; GFP, Abcam (ab290); GM130,
BD Biosciences (610822, San Jose, CA); Hoechst 3342, Life Technologies; HRP-conjugated secondary antibodies, Jackson
ImmunoResearch Laboratories (West Grove, PA) and Cell Signaling (Grand Island, NY); HSD11b2, Abcam (ab37800 and ab115696).
Small molecules were obtained from the following suppliers: 20(S)-yne Tocris Biosciences (Bristol, UK); CNX, Torcris Biosciences;
CYA, Tocris Biosciences; vismodegib, Genentech (South San Francisco, CA); SAG,MerckMillipore (Billercia, MA); SAG1.5, Cellagen
Technology (San Diego, CA); SHH, R&D Systems (Minneapolis, MN).
Sterols were obtained from Avanti Polar Lipids (Alabaster, AL). Mission short hairpin RNAs (shRNAs), which are described in
Table S1, were obtained from Sigma-Aldrich. SHH N terminus (SHHN) was produced from HEK293-SHHN stable cells as described
previously and diluted 10-fold for cell treatments (Myers et al., 2013).
Statistics
All experiments were performed with at least 3 biologic replicates. Histograms showmean ± standard error of themean. Scatterplots
show median ± 95% confidence intervals. Overall survival was estimated using the Kaplan-Meyer method and compared by Log-
rank tests. Student’s unpaired t test or Chi-square test was used, as indicated, to compare groups. In all cases, statistical signifi-
cance, as denoted by (*), was defined as p% 0.05.
Study Approval
Animal experiments were conducted in a Laboratory Animal Resource Center as per Institutional Animal Care and Use Committee
approved protocol AN098101. Human tumor samples were obtained and handled as per the Institutional Committee on Human
Research approved protocol 10-03204.e5 Molecular Cell 72, 316–327.e1–e5, October 18, 2018
